Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on PureTech Health on September 30. The company’s shares closed yesterday at $19.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Khurshid covers the Healthcare sector, focusing on stocks such as aTyr Pharma, ANI Pharmaceuticals, and Rhythm Pharmaceuticals. According to TipRanks, Khurshid has an average return of 30.4% and a 58.04% success rate on recommended stocks.
PureTech Health has an analyst consensus of Moderate Buy.
The company has a one-year high of $24.99 and a one-year low of $13.30. Currently, PureTech Health has an average volume of 4,398.
Read More on PRTC:
Disclaimer & DisclosureReport an Issue
- PureTech Health says Seaport Therapeutics doses first patient in GlyphAgo study
- Buy Rating for PureTech Health Driven by Promising LYT-100 Developments and Strategic Initiatives
- PureTech Health Reports Strong Progress and Financial Stability
- PureTech says Vedanta ulcerative colitis study missed endpoint
- PureTech falls 7% to $16.19 after founded entity study miss
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Robinhood%20app%20on%20phone%20by%20Andrew%20Neel%20via%20Unsplash.jpg)
/Nvidia%20logo%20by%20Konstantin%20Savusia%20via%20Shutterstock.jpg)
